Marshall & Sullivan Inc. WA Has $5.22 Million Holdings in Danaher Co. (NYSE:DHR)
Marshall & Sullivan Inc. WA trimmed its holdings in Danaher Co. (NYSE:DHR) by 3.4% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 36,552 shares of the conglomerate’s stock after selling 1,289 shares during the period. Danaher accounts for approximately 3.7% of Marshall & Sullivan Inc. WA’s holdings, making the stock its 5th largest position. Marshall & Sullivan Inc. WA’s holdings in Danaher were worth $5,224,000 at the end of the most recent quarter.
Several other institutional investors have also recently modified their holdings of DHR. Next Capital Management LLC acquired a new position in Danaher during the 2nd quarter valued at $31,000. Litman Gregory Asset Management LLC acquired a new position in Danaher during the 2nd quarter valued at $33,000. Lenox Wealth Management Inc. acquired a new position in Danaher during the 1st quarter valued at $40,000. Capital Advisors Ltd. LLC raised its stake in Danaher by 527.5% during the 2nd quarter. Capital Advisors Ltd. LLC now owns 320 shares of the conglomerate’s stock valued at $46,000 after purchasing an additional 269 shares during the last quarter. Finally, Contravisory Investment Management Inc. acquired a new position in Danaher during the 2nd quarter valued at $69,000. Institutional investors and hedge funds own 79.49% of the company’s stock.
Danaher stock traded down $0.10 on Wednesday, hitting $139.97. The company’s stock had a trading volume of 39,230 shares, compared to its average volume of 2,103,424. The company has a fifty day moving average price of $141.20 and a 200-day moving average price of $131.85. The company has a quick ratio of 1.91, a current ratio of 2.32 and a debt-to-equity ratio of 0.33. Danaher Co. has a one year low of $94.59 and a one year high of $145.50. The firm has a market cap of $100.68 billion, a P/E ratio of 30.97, a price-to-earnings-growth ratio of 2.53 and a beta of 0.94.
In other news, insider Brian W. Ellis sold 1,010 shares of the company’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $144.04, for a total value of $145,480.40. Following the sale, the insider now owns 20,889 shares of the company’s stock, valued at approximately $3,008,851.56. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CAO Robert S. Lutz sold 14,668 shares of the company’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $143.28, for a total transaction of $2,101,631.04. Following the completion of the sale, the chief accounting officer now directly owns 21,054 shares in the company, valued at approximately $3,016,617.12. The disclosure for this sale can be found here. In the last ninety days, insiders sold 354,316 shares of company stock worth $48,598,531. 11.40% of the stock is owned by insiders.
Several equities analysts recently commented on DHR shares. Argus upped their target price on shares of Danaher to $165.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Needham & Company LLC reiterated a “buy” rating and set a $155.00 target price (up from $142.00) on shares of Danaher in a research note on Friday, July 19th. Royal Bank of Canada set a $134.00 target price on shares of Danaher and gave the company a “hold” rating in a research note on Friday, July 19th. Robert W. Baird boosted their price target on shares of Danaher from $131.00 to $148.00 and gave the company an “outperform” rating in a report on Friday, July 19th. Finally, Wolfe Research initiated coverage on shares of Danaher in a report on Thursday, May 30th. They issued an “outperform” rating on the stock. Three research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $143.54.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Featured Story: Bear Market
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.